Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world's largest contract development and manufacturing organizations ...

New precision genome editing technologies are transforming the therapeutic landscape for patients with certain cancers and ...

The genetic code acts as life’s instruction manual, telling cells how to build proteins from DNA and RNA. Though it's a ...

Heidelberg biochemists and structural biologists from Shanghai unravel the roles of two key regulatory factors in mRNA ...

Scientists at Oak Ridge National Laboratory have developed the first-ever method of detecting ribonucleic acid, or RNA, ...

A new suggestion that complexity increases over time, not just in living organisms but in the nonliving world, promises to ...

Viruses known as “jumbo phage” are a new hope against the rising antibacterial infection crisis. Researchers have discovered ...

Biology — the science of life, living things and the processes that keep us all running — links up in essential ways with ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a disease targeted by several other firms.

The layoffs will take place throughout 2025 and will mostly affect Tenaya’s research and manufacturing operations. The ...

RNA therapeutics market is expanding, driven by advancements in gene therapy, personalized medicine, and RNA-based drug delivery, along with rising research in mRNA vaccines, antisense ...